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Abstract
Background No standard treatment has been defined for metastatic uveal melanoma (mUM). Although clinical trials testing 
Nivolumab/Pembrolizumab for cutaneous melanoma did not include mUM, anti PD-1 agents are commonly used for this 
disease.
Patients and methods In this prospective observational cohort single arm study, we investigated efficacy and safety of Pem-
brolizumab as first-line therapy for mUM. The efficacy was evaluated in terms of progression-free survival (PFS), response 
rate and overall survival (OS). Toxicity was also assessed.
Results Seventeen patients were enrolled. A median of 8 cycles were administered (range 2–28). Two patients achieved 
partial response (11.7%), 6 a disease stabilization (35.3%), whereas 9 (53%) had a progression. No complete response was 
observed. PFS of the overall population was 3.8 months. PFS was 9.7 months for patients with an interval higher than 
5 years from diagnosis of primary tumor to metastatic disease and 2.6 months for patients with an interval lower than 5 years 
[p = 0.039, HR 0.2865 (95% CI 0.0869–0.9443)]. Median OS was not reached. The two responding patients were still on treat-
ment with Pembrolizumab at the time of data analysis. Survival was 12.8 months for patients with clinical benefit, while OS 
for progressive patients was 3.1 months. PD-L1 expression and genomic abnormalities predictive of relapse after diagnosis 
of primary tumor were not associated with PFS. Toxicity was mild, without grade 3–4 side effects.
Conclusions The efficacy of Pembrolizumab does not seem particularly different when compared to other agents for mUM, 
but responding patients had a remarkable disease control.
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Abbreviations
LDH  Lactate dehydrogenase
mUM  Metastatic uveal melanoma
OS  Overall survival
PD-1  Programmed death 1
PD-L1  Programmed death ligand 1
PFS  Progression free survival
UM  Uveal melanoma
Introduction
Uveal melanoma is a rare tumor, but the most common 
malignancy of the eye [1]. Metastatic spread is frequent [2] 
despite radical treatment of the primary tumor. The liver is 
the first metastatic site as hepatic involvement represents 
about 90% of the metastatic disease [3, 4]. Liver metas-
tases are usually multifocal, limiting the possibility of a 
Some of the data presented in this paper appeared as a poster 
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loco-regional procedure [5]. The prognosis of metastatic 
disease is dismal for the majority of patients and no stand-
ard treatments have been established. Several approaches for 
metastatic uveal melanoma have been proposed, although 
they often followed clinical trials on cutaneous melanoma. 
Among the systemic therapies, chemotherapy was used with 
poor results, considering the median overall survival (OS) 
lower than 15 months [6–8]. Target agents were tested with-
out benefits [9]. After the introduction for the treatment of 
cutaneous melanoma, immune checkpoint inhibitors have 
also become a common therapy for uveal melanoma, despite 
controlled trials with immunotherapy did not include ocular 
melanoma. Ipilimumab is associated with a slight activity 
both in pre-treated and in naïve patients with metastatic 
uveal melanoma [10–12]. In pre-treated patients, Karydis 
et al. [13] reported a partial response rate of 8% and dis-
ease stabilization of 24% with Pembrolizumab, while the 
median progression-free survival (PFS) was 3  months. 
Similar results were described by Algazi et al. [14], who 
employed Pembrolizumab, Nivolumab or atezolizumab in 
48 pre-treated patients and 8 naïve patients. There are cur-
rently no available prospective clinical data with immune 
checkpoint inhibitors in a population of only naïve patients.
We have hereinafter described the preliminary results of 
a prospective observational cohort single-arm study of Pem-
brolizumab as first-line treatment in patients with metastatic 
uveal melanoma.
Patients and methods
Patients
This prospective study included patients with histologically 
proven advanced uveal melanoma. An Eastern Cooperative 
Oncology Group (ECOG) performance status of 0–2, ade-
quate bone marrow, liver and renal functions were required. 
No prior systemic anticancer treatments were allowed. Inclu-
sion and exclusion criteria are outlined in Table 1.
Pembrolizumab was administered intravenously at the 
dose of 2 mg/kg every 3 weeks, until disease progression, 
unacceptable toxicity or consent withdrawal. Toxicity was 
reported according to Common Terminology Criteria for 
Adverse Events (CTCAE vs 4.0). Baseline tumor assess-
ment with brain–chest–abdominal computed tomography 
(CT) scan or brain and abdominal magnetic resonance 
imaging (MRI) was required within 3 weeks before the first 
Pembrolizumab administration. Subsequent tumor assess-
ment was scheduled every 9 weeks until disease progression 
or discontinuation for any reason, with the possibility of 
anticipating the radiological evaluation in case of signs and 
symptoms of tumor progression.
The primary endpoint of the study was PFS. An interim 
analysis was planned after the observation of at least 50% 
cases of progression. Secondary endpoints were response 
rate, clinical benefit, OS and tolerability. Response was 
assessed according to RECIST criteria 1.1. The response 
rate included complete and partial responses. Clinical benefit 
was defined as the percentage of patients with a complete or 
partial response or disease stabilization. PFS was calculated 
from the first day of treatment to progression or death for 
any reason. Survival was defined as the interval from the 
first day of treatment to death for any cause. PFS and OS 
were calculated with the Kaplan–Meier method. The log-
rank test was employed to analyze the differences between 
patient subgroups.
Immunohistochemical evaluation
Formalin-fixed paraffin-embedded (FFPE) tissue blocks 
were retrieved from the archives of the Department of 
Pathology, Fondazione Policlinico Universitario Agostino 
Gemelli IRCCS, Rome. PD-1 and PD-L1 expression was 
evaluated using the primary Abs PD-1 (monoclonal mouse, 
NAT105, Ventana, prediluted) and PD-L1 (Kit DAKO, 
Monoclonal mouse, clone 22C3 PharmDx, prediluted). 
The slides were independently evaluated and subsequently 
analyzed by two experienced pathologists. The expression 
of PD-L1 and PD-1 was tested on primary tumor or liver 
metastasis or both, when available.
PD-L1 positivity was defined by a threshold of 5% of 
tumor cell expression. Positive cells had a strong cyto-
plasmic expression with membrane-accentuating or single 
Table 1  Inclusion and exclusion criteria
RECIST response evaluation criteria in solid tumors, ECOG Eastern 
Cooperative Oncology Group, AST aspartate aminotransferase, ALT 
alanine aminotransferase
Inclusion criteria
 Histologically confirmed advanced uveal melanoma
 At least one measurable metastases as per RECIST 1.1
 Age ≥ 18 years
 ECOG performance status ≤ 2
 Hemoglobin ≥ 12.0 g/dl; platelets ≥ 100 ×  109/l; WBC ≥ 3.0 × 109/l
 AST and ALT ≤ 2.5 ULN
 Total bilirubin ≤ 2.0 mg/dl
Exclusion criteria
 Prior systemic anticancer treatment
 History of other neoplasm
 Instable heart failure
 Serious respiratory failure
 History of rheumatic disease
 Chronic use of systemic corticosteroids
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membrane pattern [15]. Inner control was determined by 
cytoplasmic positivity for retinal pigmented epithelium cells 
as previously described [16].
Genetic analysis
DNA from uveal melanoma samples, fresh frozen or for-
malin fixed/paraffin embedded tissues, was extracted using 
DNeasy Blood & Tissue Kit (QIAGEN, Hilden, Germany). 
Oligonucleotide aCGH was performed using the Agilent 
Human Genome CGH microarray 8X60K (Agilent Tech-
nologies Santa Clara, CA, USA), with an average resolution 
of 75 kb, following the manufacturer’s instructions.
The arrays were analyzed with the SureScan Microarray 
Scanner, a graphical overview of the results was obtained 
using CytoGenomics V2.7.22.0 software (Agilent Technolo-
gies Santa Clara, CA, USA).
Results
From January 2016 to April 2018 the study enrolled 17 
patients, whose characteristics are summarized in Table 2. 
The median age was 64.7 years (ranging between 29 and 
83). Nine subjects were males and 8 females. All the patients 
had hepatic metastases. None of them had resectable liver 
metastases. Seven patients had both hepatic and extra-
hepatic disease. Ocular enucleation was previously per-
formed for the treatment of primary tumor in 12 patients, 
while Ruthenium 106 brachytherapy was carried out in 5 
patients. Four patients received a previous local treatment 
for liver metastases (metastasectomy or local ablation) at 
least 6 months before being recruited in the study. These 
patients progressed following local treatment and had a 
measurable disease when enrolled.
A median of 8 cycles per patient was administered (range 
2–28).
Two patients achieved a partial response (11.7%), 6 
patients obtained disease stabilization (35.3%), while 9 
(53%) patients showed disease progression at first tumor 
assessment (Fig. 1). The two responding patients without 
progression after 19.4 and 28.9 months, respectively, were 
still on treatment at the time of data analysis. Eight patients 
(47%) achieved clinical benefit. No complete response was 
reported.
Table 2  Patients’ characteristics
Median age (range) 63.8 years (29–83)
N. of patients
M/F 9/8 pt
Enucleation for primary tumor 12
Interval from diagnosis of primary to metastases
 > 5 years 7
 < 5 years 10
Previous local treatment for liver metastases 4
Site of metastases
 Liver 17
 Lung 6
 Bone 2
 Other 2
Hepatic and extra-hepatic metastases 7
BRAF mutation 0
Fig. 1  Waterfall chart of 
response. Black column: 
progression. Dark gray column: 
stable disease. Light gray col-
umn: partial response. Circles 
identify patients with an interval 
longer than 5 years from 
diagnosis of primary tumor to 
metastases
1182 Cancer Immunology, Immunotherapy (2019) 68:1179–1185
1 3
PFS of the whole population (Fig. 2) was 3.8 months 
(95% CI 2.9–9.7). Patients with an interval from diag-
nosis of primary tumor to metastatic disease longer than 
5 years had a PFS of 9.7 months, whereas for patients 
with an interval lower than 5 years PFS was 2.6 months 
[p = 0.039, HR 0.2865 (95% CI 0.0869–0.9443) Fig. 3a]. 
PFS was 3.1 months for patients with only liver metas-
tases, while, for patients with liver and extrahepatic 
metastases, it was 8.4 months [p = 0.65, HR 0.5811 (95% 
CI 0.1782–1.8950) Fig. 3b]. One of the two responding 
patients had only hepatic disease, while the other patients 
had both liver and extra-hepatic metastases. For the first 
patient the response was observed in liver metastases 
and in all the metastatic sites (liver, pancreas, pleura and 
lung) for the other patients. Ocular enucleation, previous 
local treatment and LDH did not influence PFS.
At the time of data cut-off for interim analysis, five 
deaths were reported. Therefore, median OS of the whole 
population was not reached. Survival for the patients 
with clinical benefit was 12.8 months and 3.1 months for 
patients with disease progression [p = 0.047, HR 0.1543 
(95% CI 0.0254–0.9377) Fig. 3c].
No grade 3–4 adverse events were observed. Grade 
2 hypophysitis was observed in one patient and grade 1 
hypothyroidism was reported in 2 patients. No diarrhea, 
rash or other cutaneous adverse events occurred.
PD‑1 and PD‑L1
We evaluated PD-1 and PD-L1 expression in 14 pri-
mary tumors and 10 metastases. PD-1 was negative in 
100% of primary tumors and 90% of metastases. PD-L1 
Fig. 2  PFS of the entire population
Fig. 3  Stratification of time-dependent clinical endpoints. a PFS of 
patients with an interval longer than 5  years from diagnosis of pri-
mary tumor to metastatic disease (dashed line) vs patients with an 
interval lower than 5 years (solid line)—p = 0.039, HR 0.2865 (95% 
CI 0.0869–0.9443). b PFS of patients with only liver metastases 
(solid line) vs PFS for patients with liver and extrahepatic disease 
(dashed line)—p = 0.65, HR 0.5811 (95% CI 0.1782–1.8950). c Sur-
vival of patients with clinical benefit (dashed line) vs survival of pro-
gressive patients (solid line)—p = 0.047, HR 0.1543 (95% CI 0.0254–
0.9377)
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was negative in 92.9% of primary tumors and 90% of 
liver metastases. One of the responding patients did not 
express PD-L1 and PD-1 either in primary uveal mela-
noma or liver metastases. Liver metastases of the other 
responding patient were PD-1 and PD-L1 negative, while 
his primary tumor sample was not available.
Genetic analysis
Genomic abnormalities are reported in Table 3. Samples for 
genetic analysis were available for 12 patients and no sig-
nificant correlation was found between genomic alterations 
and PFS. Among the responding patients, chromosome 3 
monosomy was found in association with 8q duplication in 
one of the patients.
Discussion
Metastatic uveal melanoma is a poor-prognosis disease. To 
date, remarkable advantages of a systemic therapy have not 
been reported and a standard treatment has not been estab-
lished. Although uveal melanoma was ruled out in controlled 
clinical trials, this neoplasm is commonly treated as a cuta-
neous melanoma, despite the different clinical and biological 
features. BRAF is often wild type, thus also excluding the 
possibility of a treatment with BRAF/MEK inhibitors.
Immunotherapy is one of the options for this disease, par-
ticularly chosen for the favorable toxicity profile. The avail-
able studies on anti-PD-1 agents in mUM are retrospective 
and included pre-treated patients [13, 14, 17], while there is 
a lack of prospective data on naïve patients only. We have 
evaluated Pembrolizumab, an anti-PD-1 monoclonal anti-
body, as first-line treatment for advanced uveal melanoma.
In the present study, the response rate was 11.7%. More 
than half of the patients experienced a progression at first 
tumor assessment. The objective response rate was lower 
than in cutaneous melanoma treated with pembrolizumab 
(32.9%), despite the different schedule used [18]. In our 
previous study on the efficacy and safety of a triple-agent 
chemotherapy, we found a 20% response rate, a 68% clini-
cal benefit and a survival advantage for patients achieving 
tumor control [19]. The results in the chemotherapy study 
could be justified by the selected population suitable for a 
cisplatin-based combination chemotherapy.
In our population treated with Pembrolizumab, two 
responding patients were still alive for at least 19 months, 
suggesting a possible survival advantage in case of tumor 
shrinkage.
The median PFS of the entire population in our study 
(3.8 months) was similar to the PFS reported by Karidis 
et  al. [13] (91  days) and slightly longer than the PFS 
described by Algazy et al. [14] (2.6 months) in their retro-
spective analyses.
The patients with an interval from the diagnosis of pri-
mary tumor to metastases longer than 5 years had a sig-
nificant prolonged PFS compared to patients with an inter-
val lower than 5 years (9.8 months vs 3.7 months). In UM, 
relapse may occur more than 5 years after treatment of the 
primary tumor [20]. It was suggested that immune-surveil-
lance through T cell activity is a mechanism which explains 
the late recurrence [20, 21]. Therefore, our aim was to verify 
the different efficacy of immunotherapy in patients relapsing 
within 5 years compared to patients with later recurrence. 
Table 3  Genetic abnormalities
CNVs chromosome number variants, TOT VAR total variants, WCAD whole chromosome arm deletion/duplication, PCAD partial chromosome 
arm deletion/duplication
a Entire arm, partial or complete chromosome 8 trisomy
Pts Monosomy 3 8q  duplicationa Gross rearrangements: monosomy, trisomy, 
WCAD and/or PCAD
Other CNVs TOT VAR
#2 Y Y 5 (1q+,8p−,16p+,16q−,18q−) 2 9
#3 Y Y 3 (1p−,16q−,21q−) 20 25
#4 Y Y 2 (8p−,−19) 28 32
#5 Y Y 2 (1p−,4q−) 4
#6 Y Y 1 (17p−) 1 4
#7 Y 6 (1p−,+7,−11,−14,−15,−21) 7
#8 Y Y 4 (4p+,7p+,8p−,16q−) 8 14
#9 5 (1p−,6p+,6q−,13q+,16q−) 5
#10 Y Y 2 (6q−,8p−) 2 6
#11 Y 8 (1q+,4q+,6p+,6q−8p−,9p−,9q+,12p−) 4 13
#14 Y 5 (1p−,6p+,6q−13q+,16q−) 8 14
#17 Y Y 4 (4p+,8p−,16q−,+19) 15 21
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Based on our data, relapse after 5 years from the diagnosis 
of primary tumor could be considered a parameter to select 
patients who may benefit more from immunotherapy.
In our study, patients with extra-hepatic disease showed 
a longer PFS than patients with only liver metastases. 
Although not statically significant, this datum seems to 
confirm the results in pre-treated patients [3], suggesting a 
role of immunotherapy mainly in patients with extra-hepatic 
disease. The possibility of immune escape in patients with 
only liver metastases could justify this observation [22].
We confirmed the favorable toxicity profile of Pembroli-
zumab in metastatic uveal melanoma.
The small number of patients responding to Pembroli-
zumab showed a remarkable survival advantage. Therefore, 
the identification of predictive factors for response is cru-
cial. In our study, basal LDH did not correlate with PFS, in 
contrast with the results reported by Heppt et al. [17]. As 
possible predictive factors, we also evaluated both PD-L1 
expression and genomic abnormalities commonly involved 
in the risk of relapse after the diagnosis of primary UM.
In our series, we found a limited expression of PD-L1 
both in primary tumor and in metastases (7.1% and 10%, 
respectively). Few reports are available on PD-L1 expres-
sion in UM. Zoroquiain et al. [15] reported a 40% PD-L1 
expression on tumor cells of primary UM in patients with 
metastatic disease. On the other hand, similar to our data, 
Javed et al. [23] observed that only 5% of uveal melanoma 
expresses PD-L1 in the metastatic sites. The responders in 
our study did not express PD-L1 either in primary tumor or 
metastases, thus PD-L1 could not be considered a predictive 
factor for these patients.
Regarding the genetic results, different genomic altera-
tions, such as chromosome 3 monosomy and gains of chro-
mosome 8q, are predictive of relapse after primary treatment 
[24–28]. In this study, we analysed the association between 
these genomic alterations with PFS. The genomic alterations 
found in 12 metastatic patients did not allow to identify spe-
cific abnormalities correlated with PFS. This result seems to 
suggest that the genetic prognostic factors, commonly pre-
dictive of relapse after treatment of the primary tumor, are 
not useful in predicting the efficacy of Pembrolizumab for 
metastatic disease.
It has recently been reported that a defect of MBD4, a 
transcriptional factor of gene promoters, is associated with 
a hypermutated CpG > TpG pattern which generates multi-
ple subclones of the primary UM with more heterogeneous 
metastases. A patient with this MBD4-related hypermuta-
tor phenotype showed a remarkable response to immune 
checkpoint inhibitors [29]. Indeed, this evidence implies 
that specific and selected subgroups of UM could benefit 
from immunotherapy.
Due to the rarity of the disease, the small sample size 
of the study limits the interpretation of the data. Results 
regarding survival and patients still on treatment could pro-
vide further information.
Pembrolizumab is a well-tolerated agent which allows 
to obtain an objective response in metastatic uveal mela-
noma only in a minority of patients. These patients could 
benefit from a long-term disease control. Further investiga-
tions on the biological characteristics of uveal melanoma 
are essential to select patients who could benefit more from 
immunotherapy.
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